The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II.
I. Chau
Consultant or Advisory Role - Merck Serono (U); Roche
Honoraria - Pfizer; Roche; Sanofi
Research Funding - Merck Serono; Roche
A. F. C. Okines
Honoraria - Roche
D. Gonzalez de Castro
No relevant relationships to disclose
C. Saffery
No relevant relationships to disclose
Y. Barbachano
No relevant relationships to disclose
A. Wotherspoon
No relevant relationships to disclose
L. Puckey
No relevant relationships to disclose
S. Hulkki Wilson
No relevant relationships to disclose
F. Y. Coxon
Research Funding - Roche
G. W. Middleton
No relevant relationships to disclose
D. R. Ferry
Honoraria - Amgen
Research Funding - Amgen
T. D. L. Crosby
Consultant or Advisory Role - Roche
S. Madhusudan
No relevant relationships to disclose
J. Wadsley
No relevant relationships to disclose
J. S. Waters
No relevant relationships to disclose
M. Hall
No relevant relationships to disclose
D. Swinson
No relevant relationships to disclose
A. Robinson
No relevant relationships to disclose
D. Smith
No relevant relationships to disclose
D. Cunningham
Consultant or Advisory Role - Amgen; Roche (U)
Research Funding - Amgen; Merck Serono; Roche; Sanofi